The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
Open accessAbstract
BACKGROUND: Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead. We investigated the hypothesis that the addition of clopidogrel to aspirin would reduce the risk of vascular events in patients with atrial fibrillation. METHODS: A total of 7554 patients with atrial fibrillation who had an increased risk of stroke and for whom vitamin K-antagonist therapy was unsuitable were randomly assigned to receive clopidogrel (75 mg) or placebo, once daily, in addition to aspirin. The primary outcome was the composite of stroke, myocardial infarction, non-central nervous system systemic embolism, or death from vascular causes. RESULTS: At a median of 3.6 years of follow-up, major vascular events had occurred in 832 patients receiving clopidogrel (6.8% per year) and in 924 patients receiving placebo (7.6% per year) (relative risk with clopidogrel, 0.89; 95% confidence interval [CI], 0.81 to 0.98; P=0.01). The difference was primarily due to a reduction in the rate of stroke with clopidogrel. Stroke occurred in 296 patients receiving clopidogrel (2.4% per year) and 408 patients receiving placebo (3.3% per year) (relative risk, 0.72; 95% CI, 0.62 to 0.83; P<0.001). Myocardial infarction occurred in 90 patients receiving clopidogrel (0.7% per year) and in 115 receiving placebo (0.9% per year) (relative risk, 0.78; 95% CI, 0.59 to 1.03; P=0.08). Major bleeding occurred in 251 patients receiving clopidogrel (2.0% per year) and in 162 patients receiving placebo (1.3% per year) (relative risk, 1.57; 95% CI, 1.29 to 1.92; P<0.001). CONCLUSIONS: In patients with atrial fibrillation for whom vitamin K-antagonist therapy was unsuitable, the addition of clopidogrel to aspirin reduced the risk of major vascular events, especially stroke, and increased the risk of major hemorrhage. (ClinicalTrials.gov number, NCT00249873.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Antiplatelet therapy increases bleeding risk, especially dual antiplatelet therapy (2.0% vs. 1.3% with antiplatelet monotherapy; P < 0.001), 433 with bleeding rates that are similar to those on OAC.354,362,431,434”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [433]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atrial fibrillation as an independent risk factor for stroke: the Framingham study
Wolf, P. A., Abbott, R. D., & Kannel, W. B. (1991) · Stroke · doi:10.1161/01.str.22.8.983 · Cited by 7,388
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Self-citationHart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67660-x · Cited by 1,858
Fuster, V., Rydén, L., Cannom, D. S., Crijns, H. J. G. M., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Heuzey, J. L., Kay, G. N., Lowe, J. E., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.009 · Cited by 1,161
Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited
Watson, T., Shantsila, E., & Lip, G. Y. H. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60040-4 · Cited by 1,124
Antithrombotic Therapy in Atrial Fibrillation
Singer, D. E., Albers, G. W., Dalen, J. E., Fang, M. C., Go, A. S., Halperin, J. L., Lip, G. Y. H., & Manning, W. J. (2008) · CHEST Journal · doi:10.1378/chest.08-0678 · Cited by 758
Oral Anticoagulants vs Aspirin in Nonvalvular Atrial Fibrillation
van Walraven, C., Hart, R. G., Singer, D. E., Laupacis, A., Connolly, S. J., Petersen, P., Koudstaal, P. J., Chang, Y., & Hellemons, B. S. P. (2002) · JAMA · doi:10.1001/jama.288.19.2441 · Cited by 715
Cannon, C. P., Battler, A., Brindis, R. G., Cox, J. L., Ellis, S. G., Every, N. R., Flaherty, J. T., Harrington, R. A., Krumholz, H. M., Simoons, M. L., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01702-8 · Cited by 673
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 1,000
Borne, R. T., O’Donnell, C. I., Turakhia, M. P., Varosy, P. D., Jackevicius, C. A., Marzec, L., Masoudi, F. A., Hess, P. L., Maddox, T. M., & Ho, P. M. (2017) · BMC Cardiovascular Disorders · doi:10.1186/s12872-017-0671-6 · Cited by 162
Hachamovitch, R. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.121 · Cited by 155
Atrial fibrillation burden: a new outcome predictor and therapeutic target
Becher, N., Metzner, A., Toennis, T., Kirchhof, P. F., & Schnabel, R. B. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae373 · Cited by 169
“66 The reductions in mortality seen in anticoagulation trials 63,67 suggest that stroke prevention can reduce cardiovascular deaths.”
BackgroundNtaios, G., Papavasileiou, V., Diener, H.-C., Makaritsis, K., & Michel, P. (2012) · Stroke · doi:10.1161/strokeaha.112.673558 · Cited by 152
Pan, K., Singer, D. E., Ovbiagele, B., Wu, Y., Ahmed, M., & Lee, M. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005835 · Cited by 155
National Assessment of Warfarin Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation
Dlott, J. S., George, R., Huang, X., Odeh, M. A., Kaufman, H. W., Ansell, J., & Hylek, E. M. (2014) · Circulation · doi:10.1161/circulationaha.113.002601 · Cited by 154
Low Doses of Acetylsalicylic Acid Increase Risk of Gastrointestinal Bleeding in a Meta-Analysis
Lanas, Á., Wu, P., Medin, J., & Mills, E. J. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.05.020 · Cited by 152
The Secondary Prevention of Small Subcortical Strokes (SPS3) Study
Benavente, O., White, C. L., Pearce, L. A., Pérgola, P. E., Roldan, A., Benavente, M.-F., Coffey, C. S., McClure, L. A., Szychowski, J. M., CONWIT, R. A., et al. (2011) · International Journal of Stroke · doi:10.1111/j.1747-4949.2010.00573.x · Cited by 153
Chan, Y., See, L., Tu, H., Yeh, Y., Chang, S., Wu, L., Lee, H., Wang, C., Kuo, C., & Kuo, C.-T. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.008150 · Cited by 155
Huisman, M. V., Lip, G. Y. H., Diener, H., Dubner, S., Halperin, J. L., Chang, S., Rothman, K. J., Teutsch, C., Zint, K., Ackermann, D., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.12.006 · Cited by 148
Adverse Drug Events as a Cause of Hospitalization in Older Adults
Salvi, F., Marchetti, A., D’Angelo, F., Boemi, M., Lattanzio, F., & Cherubini, A. (2012) · Drug Safety · doi:10.1007/bf03319101 · Cited by 153
Comparative Efficacy and Safety of New Oral Anticoagulants in Patients With Atrial Fibrillation
Schneeweiß, S., Gagne, J. J., Patrick, A. R., Choudhry, N. K., & Avorn, J. (2012) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.112.965988 · Cited by 146
Site-Level Variation in and Practices Associated With Dabigatran Adherence
Shore, S., Ho, P. M., Lambert‐Kerzner, A., Glorioso, T. J., Carey, E., Cunningham, F., Longo, L., Jackevicius, C. A., Rose, A. J., & Turakhia, M. P. (2015) · JAMA · doi:10.1001/jama.2015.2761 · Cited by 145
Proton Pump Inhibitor and Clopidogrel Interaction: Fact or Fiction?
Laine, L., & Hennekens, C. H. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.638 · Cited by 143
Atrial Fibrillation and Thromboembolism in Patients With Chronic Kidney Disease
Lau, Y. C., Proietti, M., Guiducci, E., Blann, A. D., & Lip, G. Y. H. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.06.057 · Cited by 145
Rationale and design of the Left Atrial Appendage Occlusion Study (LAAOS) III.
Whitlock, R. P., Healey, J. S., Vincent, J., Brady, K., Teoh, K., Royse, A. G., Shah, P. J., Guo, Y., Alings, M., Folkeringa, R., et al. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2225-319x.2013.12.06 · Cited by 144
“Aspirin and Plavix, ACTIVE A (45) [3,772] 2.”
BackgroundAntithrombotic Therapy in the Elderly
Capodanno, D., & Angiolillo, D. J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.04.063 · Cited by 142
Genetics of Ischemic Stroke, Stroke-Related Risk Factors, Stroke Precursors and Treatments
Della‐Morte, D., Guadagni, F., Palmirotta, R., Testa, G., Caso, V., Paciaroni, M., Abete, P., Rengo, F., Ferroni, P., Sacco, R. L., et al. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.14 · Cited by 143
Friedman, R. J., Dahl, O. E., Rosencher, N., Caprini, J. A., Kurth, A. A., Francis, C. W., Clemens, A., Hantel, S., Schnee, J. M., & Eriksson, B. I. (2010) · Thrombosis Research · doi:10.1016/j.thromres.2010.03.021 · Cited by 141
Connolly, S. J., Eikelboom, J. W., Ng, J., Hirsh, J., Yusuf, S., Pogue, J., de Caterina, R., Hohnloser, S., & Hart, R. G. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-9-201111010-00004 · Cited by 140
Stroke Prevention and Treatment
Marsh, J. D., & Keyrouz, S. G. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.12.072 · Cited by 147
Hogan, D. F., Fox, P. R., Jacob, K. A., Keene, B. W., Laste, N. J., Rosenthal, S., Sederquist, K. A., & Weng, H. (2015) · Journal of Veterinary Cardiology · doi:10.1016/j.jvc.2015.10.004 · Cited by 157
Chiang, C., Wu, T.-J., Ueng, K.-C., Chao, T., Chang, K., Wang, C.-C., Lin, Y., Yin, W., Kuo, J., Lin, W., et al. (2016) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2016.10.005 · Cited by 138
Pharmacogenetics and Cardiovascular Disease—Implications for Personalized Medicine
Johnson, J. A., & Cavallari, L. H. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.007252 · Cited by 141
“The atrial fibrillation population from ACTIVE-A obtained an 11% risk reduction with clopidogrel (Connolly et al., 2009).”
BackgroundVerheugt, F. W. A., & Granger, C. B. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60245-8 · Cited by 137
Görenek, B., Lundqvist, C. B., Brugada, J., Camm, A. J., Hindricks, G., Huber, K., Kirchhof, P. F., Kück, K., Kudaiberdieva, G., Lin, T., et al. (2014) · EP Europace · doi:10.1093/europace/euu208 · Cited by 134
Thigpen, J. L., Dillon, C., Forster, K., Henault, L. E., Quinn, E. K., Tripodis, Y., Berger, P. B., Hylek, E. M., & Limdi, N. A. (2015) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.113.000371 · Cited by 138
Hsu, J. C., Maddox, T. M., Kennedy, K. F., Katz, D. F., Marzec, L., Lubitz, S. A., Gehi, A. K., Turakhia, M. P., & Marcus, G. M. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.581 · Cited by 133
Culebras, A., Messe, S. R., Chaturvedi, S., Kase, C. S., & Gronseth, G. (2014) · Neurology · doi:10.1212/wnl.0000000000000145 · Cited by 133
Triple Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Stents
Paikin, J. S., Wright, D. S., Crowther, M. A., Mehta, S. R., & Eikelboom, J. W. (2010) · Circulation · doi:10.1161/circulationaha.109.924944 · Cited by 131
Is There an Obesity Paradox for Outcomes in Atrial Fibrillation?
Proietti, M., Guiducci, E., Cheli, P., & Lip, G. Y. H. (2017) · Stroke · doi:10.1161/strokeaha.116.015984 · Cited by 131
Oral anticoagulation use by patients with atrial fibrillation in Germany
Wilke, T., Groth, A., Mueller, S., Pfannkuche, M., Verheyen, F., Linder, R., Maywald, U., Kohlmann, T., Feng, Y., BREITHARDT, G. E., et al. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-11-0768 · Cited by 129
Lópes, R. D., Hylek, E. M., & Garcia, D. A. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-07-0491 · Cited by 130
The role of aspirin for stroke prevention in atrial fibrillation
Lip, G. Y. H. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.112 · Cited by 136
High-Sensitivity Troponin I for Risk Assessment in Patients With Atrial Fibrillation
Hijazi, Z., Siegbahn, A. G., Andersson, U., Granger, C. B., Alexander, J. H., Atar, D., Gersh, B. J., Mohan, P., Harjola, V., Horowitz, J. D., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.006286 · Cited by 128
Görenek, B., Lundqvist, C. B., Brugada, J., Camm, A. J., Hindricks, G., Huber, K., Kirchhof, P. F., Kück, K., Kudaiberdieva, G., Lin, T., et al. (2014) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872614550583 · Cited by 128
Evolving use of new oral anticoagulants for treatment of venous thromboembolism
Yeh, C. H., Gross, P. L., & Weitz, J. I. (2014) · Blood · doi:10.1182/blood-2014-03-563056 · Cited by 129
Noninvasive Cardiac Event Monitoring to Detect Atrial Fibrillation After Ischemic Stroke
Higgins, P., Macfarlane, P. W., Dawson, J., McInnes, G. T., Langhorne, P., & Lees, K. R. (2013) · Stroke · doi:10.1161/strokeaha.113.001927 · Cited by 127
Spontaneous Intracerebral Hemorrhage: Management
Kim, J. Y., & Bae, H. (2017) · Journal of Stroke · doi:10.5853/jos.2016.01935 · Cited by 131
“In patients with nonlobar ICH, antiplatelet monotherapy can be a safer alternative to VKA in some patients with atrial fibrillation.(4,51,52) As alternatives to VKA after ICH, the usefulness of NOACs including dabigatran, rivaroxaban, and apixaban, remains unknown.”
BackgroundBai, Y., Deng, H., Shantsila, A., & Lip, G. Y. H. (2017) · Stroke · doi:10.1161/strokeaha.116.016275 · Cited by 128
Fernando, H. C., Jaklitsch, M. T., Walsh, G. L., Tisdale, J. E., Bridges, C. D., Mitchell, J. D., & Shrager, J. B. (2011) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2011.06.104 · Cited by 125
Sanghai, S., Wong, C. H., Wang, Z., Clive, P. H., Tran, W., Waring, M. E., Goldberg, R. J., Hayward, R., Saczynski, J. S., & McManus, D. D. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014108 · Cited by 123
Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation
Bekwelem, W., Connolly, S. J., Halperin, J. L., Adabağ, S., Duval, S., Chrolavicius, S., Pogue, J. M., Ezekowitz, M. D., Eikelboom, J. W., Wallentin, L. C., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.013243 · Cited by 122
The Use of Dabigatran Immediately After Atrial Fibrillation Ablation
Winkle, R. A., Mead, R. H., Engel, G., Kong, M. H., & Patrawala, R. A. (2011) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.2011.02175.x · Cited by 122
The Role of Clopidogrel in 2020: A Reappraisal
Patti, G., Micieli, G., Cimminiello, C., & Bolognese, L. (2020) · Cardiovascular Therapeutics · doi:10.1155/2020/8703627 · Cited by 129
Decrease in the oral bioavailability of dabigatran etexilate after co‐medication with rifampicin
Härtter, S., Koenen‐Bergmann, M., Sharma, A., Nehmiz, G., Lemke, U., Timmer, W., & Reilly, P. A. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04218.x · Cited by 120
Brown, S.-A. N., & Pereira, N. L. (2018) · Journal of Personalized Medicine · doi:10.3390/jpm8010008 · Cited by 124
“Similar observations were made in another study that involved patients with atrial fibrillation, in which no correlation was seen between CYP2C19 loss-of-function or gain-of-function variant status and cardiovascular outcomes in patients on clopidogrel [115].”
ResultWithdrawal of Antithrombotic Agents and Its Impact on Ischemic Stroke Occurrence
Broderick, J. P., Bonomo, J., D, B. M. K. M., Khoury, J. C., Moomaw, C. J., Alwell, K., Woo, D., Flaherty, M. L., Khatri, P., Adeoye, O. M., et al. (2011) · Stroke · doi:10.1161/strokeaha.110.611905 · Cited by 119
Combination Antithrombotic Therapies
Gurbel, P. A., & Tantry, U. S. (2010) · Circulation · doi:10.1161/circulationaha.109.853085 · Cited by 121
Chao, T., Liu, C., Liao, J., Wang, K.-L., Lin, Y., Chang, S., Lo, L., Hu, Y., Tuan, T., Chung, F., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.019794 · Cited by 117
Reis, A. M. M., & Cassiani, S. H. D. B. (2011) · Clinics · doi:10.1590/s1807-59322011000100003 · Cited by 116
Atrial Fibrillation and Ischemic Stroke: A Clinical Review
Migdady, I., Russman, A., & Buletko, A. B. (2021) · Seminars in Neurology · doi:10.1055/s-0041-1726332 · Cited by 130
PASSMAN, R., LEONG‐SIT, P., ANDREI, A., HUSKIN, A., TOMSON, T. T., BERNSTEIN, R., ELLIS, E., WAKS, J. W., & ZIMETBAUM, P. (2016) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.12864 · Cited by 115
Kefer, J., Tzikas, A., Freixa, X., Shakir, S., Gafoor, S. A., Nielsen‐Kudsk, J. E., Berti, S. L., Santoro, G., Aminian, A., Landmesser, U., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.01.003 · Cited by 115
Durães, A. R., Roriz, P. D. S., Nunes, B. D. A., Albuquerque, F. P. E., de Bulhões, F. V., Fernandes, A. M. S., & Aras, R. (2016) · Drugs in R&D · doi:10.1007/s40268-016-0124-1 · Cited by 114
Wang, Y., Zhang, S., Zhang, L., & Wang, C. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2011.00290.x · Cited by 113
Cameron, C. G., Coyle, D., Richter, T. A., Kelly, S., Gauthier, K., Steiner, S., Carrier, M., Coyle, K., Bai, A., Moulton, K., et al. (2014) · BMJ Open · doi:10.1136/bmjopen-2013-004301 · Cited by 113
Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)
Gelosa, P., Castiglioni, L., Tenconi, M., Baldessin, L., Racagni, G., Corsini, A., & Bellosta, S. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.07.016 · Cited by 113
Lip, G. Y. H., Noack, H., Clemens, A., Plumb, J. M., & Roskell, N. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-10-0642 · Cited by 111
Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients
Sellers, M., & Newby, L. K. (2011) · American Heart Journal · doi:10.1016/j.ahj.2010.11.002 · Cited by 111
Baker, W. L., & Phung, O. J. (2012) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.112.966572 · Cited by 111
Shared Decision Making in Atrial Fibrillation
Seaburg, L., Hess, E. P., Coylewright, M. J., Ting, H. H., McLeod, C. J., & Montori, V. M. (2014) · Circulation · doi:10.1161/circulationaha.113.004498 · Cited by 109
Ng, K. H., Shestakovska, O., Connolly, S. J., Eikelboom, J. W., Avezum, Á., Díaz, R., Lanas, F. T., Yusuf, S., & Hart, R. G. (2015) · Age and Ageing · doi:10.1093/ageing/afv156 · Cited by 113
Evolving Treatments for Arterial and Venous Thrombosis
Chan, N., Eikelboom, J. W., & Weitz, J. I. (2016) · Circulation Research · doi:10.1161/circresaha.116.306925 · Cited by 113
Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation
Abdul‐Rahim, A. H., Moreno, A. C. P., Fulton, R. L., Jhund, P. S., Latini, R., Tognoni, G., Wikstrand, J., KJEKSHUS, J. K., Lip, G. Y. H., Maggioni, A. P., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.013760 · Cited by 114
Periprocedural Management and Approach to Bleeding in Patients Taking Dabigatran
Weitz, J. I., Quinlan, D. J., & Eikelboom, J. W. (2012) · Circulation · doi:10.1161/circulationaha.112.123224 · Cited by 109
Non‐adherence to new oral anticoagulants: a reason for concern during long‐term anticoagulation?
Rodriguez, R. A., Carrier, M., & Wells, P. S. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12086 · Cited by 110
Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Coronary Stenting
Faxon, D. P., Eikelboom, J. W., Berger, P. B., Holmes, D. R., Bhatt, D. L., Moliterno, D. J., Becker, R. C., & Angiolillo, D. J. (2011) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.111.965186 · Cited by 108
Tanigawa, T., Kaneko, M., Hashizume, K., Kajikawa, M., Ueda, H., Tajiri, M., Paolini, J. F., & Mueck, W. (2012) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-12-rg-034 · Cited by 111
Cerebral amyloid angiopathy–associated intracerebral hemorrhage: pathology and management
Mehndiratta, P., Manjila, S. V., Ostergard, T. A., Eisele, S. C., Cohen, M. L., Sila, C. A., & Selman, W. R. (2012) · Neurosurgical FOCUS · doi:10.3171/2012.1.focus11370 · Cited by 107
Lip, G. Y. H., Pan, X., Kamble, S., Kawabata, H., Mardekian, J., Masseria, C., Bruno, A. S., & Phatak, H. M. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12863 · Cited by 106
Antithrombotic Therapy for Primary and Secondary Prevention of Ischemic Stroke
Greco, A., Occhipinti, G., Giacoppo, D., Agnello, F. G., Laudani, C., Spagnolo, M., Mauro, M. S., Rochira, C., Finocchiaro, S., Mazzone, P. M., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.07.025 · Cited by 115
Mechanisms of Stroke in Patients with Chronic Kidney Disease
Ghoshal, S., & Freedman, B. I. (2019) · American Journal of Nephrology · doi:10.1159/000502446 · Cited by 106
Does Warfarin for Stroke Thromboprophylaxis Protect Against MI in Atrial Fibrillation Patients?
Lip, G. Y. H., & Lane, D. A. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.01.031 · Cited by 103
Wann, L. S., Curtis, A. B., January, C. T., Ellenbogen, K. A., Lowe, J. E., Estes, N. A. M., Page, R. L., Ezekowitz, M. D., Slotwiner, D. J., Jackman, W. M., et al. (2010) · Heart Rhythm · doi:10.1016/j.hrthm.2010.11.047 · Cited by 103
Sánchez, M. A., Bertoméu, V., & Cequier, A. R. (2015) · Revista Española de Cardiología · doi:10.1016/j.recesp.2014.11.022 · Cited by 101
Douxfils, J., Buckinx, F., Mullier, F., Minet, V., Rabenda, V., Reginster, J., Hainaut, P., Bruyère, O., & Dogné, J. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000515 · Cited by 103
EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer
Falanga, A., Leader, A., Ambaglio, C., Bagoly, Z., Castaman, G., Elalamy, I., Lecumberri, R., Niessner, A., Pabinger, I., Szmit, S., et al. (2022) · HemaSphere · doi:10.1097/hs9.0000000000000750 · Cited by 106
Shehab, N., Sperling, L. S., Kegler, S. R., & Budnitz, D. S. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.407 · Cited by 102
Albertsen, I. E., Rasmussen, L. H., Overvad, T. F., Graungaard, T., Larsen, T. B., & Lip, G. Y. H. (2013) · Stroke · doi:10.1161/strokeaha.113.000883 · Cited by 101
Extracorporeal Therapy for Dabigatran Removal in the Treatment of Acute Bleeding
Singh, T., Maw, T. T., Henry, B. L., Pastor‐Soler, N. M., Unruh, M. L., Hallows, K. R., & Nolin, T. D. (2013) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01570213 · Cited by 101
Paciaroni, M., Agnelli, G., Caso, V., Silvestrelli, G., Seiffge, D. J., Engelter, S. T., Marchis, G. M. D., Polymeris, A. A., Zedde, M., Yaghi, S. R., et al. (2019) · Stroke · doi:10.1161/strokeaha.119.025350 · Cited by 102
Adherence to anticoagulant treatment with dabigatran in a real‐world setting
Schulman, S., Shortt, B., Robinson, M., & Eikelboom, J. W. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12241 · Cited by 99
Grottke, O., van Ryn, J., Spronk, H. M. H., & Rossaint, R. (2014) · Critical Care · doi:10.1186/cc13717 · Cited by 99
Zakko, L., Rustagi, T., Douglas, M., & Laine, L. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.07.017 · Cited by 99
Okumura, Y., Yokoyama, K., Matsumoto, N., Tachibana, E., Kuronuma, K., Oiwa, K., Matsumoto, M., Kojima, T., Hanada, S., Nomoto, K., et al. (2017) · Journal of Arrhythmia · doi:10.1016/j.joa.2016.11.003 · Cited by 99
Santoro, G., Meucci, F., Stolcova, M., Rezzaghi, M., Mori, F., Palmieri, C., Paradossi, U., Pastormerlo, L. E., Rosso, G., & Berti, S. (2016) · EuroIntervention · doi:10.4244/eijy14m10_12 · Cited by 97
Ferreira, J., Ezekowitz, M. D., Connolly, S. J., Brueckmann, M., Fraessdorf, M., Reilly, P. A., Yusuf, S., & Wallentin, L. C. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft111 · Cited by 96
Time to Cost-Effectiveness Following Stroke Reduction Strategies in AF
Reddy, V. Y., Akehurst, R. L., Armstrong, S. O., Amorosi, S. L., Beard, S. M., & Holmes, D. R. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.09.084 · Cited by 99
Posma, J., Grover, S. P., Hisada, Y., Owens, A. P., Antoniak, S., Spronk, H. M. H., & Mackman, N. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311655 · Cited by 100
Bajaj, N. S., Parashar, A., Agarwal, S., Sodhi, N., Poddar, K. L., Garg, A., Tuzcu, E. M., & Kapadia, S. R. (2014) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2013.11.010 · Cited by 97
Recent Safety Concerns With Proton Pump Inhibitors
Chen, J. W., Yuan, Y., Leontiadis, G. I., & Howden, C. W. (2012) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3182333820 · Cited by 95
Lee, H., Chan, Y., Chang, S., Tu, H., Chen, S., Yeh, Y., Wu, L., Kuo, C., Kuo, C.-T., & See, L. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011112 · Cited by 94
AlTurki, A., Marafi, M., Proietti, R., Cardinale, D. M., Blackwell, R. H., Dorian, P., Bessissow, A., Vieira, L., Greiss, I., Essebag, V., et al. (2020) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.119.007437 · Cited by 94
Stroke in atrial fibrillation: epidemiology and thromboprophylaxis
Lip, G. Y. H. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04302.x · Cited by 91
Dabigatran Versus Warfarin for Atrial Fibrillation in Real-World Clinical Practice
Romanelli, R. J., Nolting, L., Dolginsky, M., Kym, E., & Orrico, K. B. (2016) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.115.002369 · Cited by 92
Dabigatran in real-world atrial fibrillation
Costa, F. M., Ferreira, J., Mendes, M., & Carmo, J. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-03-0203 · Cited by 91
Angiolillo, D. J., Goodman, S. G., Bhatt, D. L., Eikelboom, J. W., Price, M. J., Moliterno, D. J., Cannon, C. P., Tanguay, J., Granger, C. B., Mauri, L., et al. (2016) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.116.004395 · Cited by 90
“OAC is the treatment of choice if clinically indicated and feasible.(26,27) Therefore, clinicians commonly treat PCI patients”
BackgroundIncreasing incidence of chronic subdural haematoma in the elderly
Adhiyaman, V., Chattopadhyay, I., Irshad, F., Curran, D. B., & Abraham, S. (2017) · QJM · doi:10.1093/qjmed/hcw231 · Cited by 90
Pharmacogenetics of dabigatran etexilate interindividual variability
Dimatteo, C., D’Andrea, G., Vecchione, G., Paoletti, O., Cappucci, F., Tiscia, G. L., Buono, M., Grandone, E., Testa, S., & Margaglione, M. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.05.025 · Cited by 90
Metadata
- Authors
- The ACTIVE Investigators
- Affiliations
- Population Health Research Institute (CA)
- Corresponding author
- The ACTIVE Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-05-14
- Volume
- 360
- Issue
- 20
- Pages
- 2066-2078
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2113089341
- Cited by
- 2,102
- References
- 25
- Citations by year
- 2026: 10 · 2025: 16 · 2024: 25 · 2023: 19 · 2022: 23 · 2021: 55 · 2020: 65 · 2019: 73 · 2018: 75 · 2017: 115 · 2016: 166 · 2015: 205 · 2014: 209 · 2013: 264 · 2012: 286
- FWCI
- 168.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
- Own your potential (DEAKIN) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion)
- UnissResearch (Università degli Studi di Sassari) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- clopidogrel, aspirin, atrial fibrillation, stroke prevention, antiplatelet therapy, vitamin K antagonists, myocardial infarction, major bleeding, vascular events, systemic embolism, anticoagulation alternatives, bleeding risk, stroke risk reduction, quality of life, cost-effectiveness
- MeSH terms
- Clopidogrel, Aged, Aspirin, Atrial Fibrillation, Double-Blind Method, Drug Therapy, Combination, Embolism, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Myocardial Infarction, Platelet Aggregation Inhibitors, Risk, Ticlopidine, Vascular Diseases, Vitamin K, Incidence, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
